| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883196 | AGILE | Transdermal hormone delivery system: compositions and methods |
Nov, 2020
(3 years ago) | |
| US7045145 | AGILE | Transdermal contraceptive delivery system and process |
Mar, 2021
(3 years ago) | |
| US8221784 | AGILE | Transdermal hormone delivery system: compositions and methods |
Mar, 2021
(3 years ago) | |
| US7384650 | AGILE | Skin permeation enhancement composition for transdermal hormone delivery system |
Mar, 2021
(3 years ago) | |
| US8221785 | AGILE | Transdermal hormone delivery system: compositions and methods |
Mar, 2021
(3 years ago) | |
| US8747888 | AGILE | Dermal delivery device with in situ seal |
Jul, 2028
(4 years from now) | |
| US9050348 | AGILE | Dermal delivery device |
Jul, 2028
(4 years from now) | |
| US8246978 | AGILE | Dermal delivery device with reduced loss of its volatile components |
Aug, 2028
(4 years from now) | |
Twirla is owned by Agile.
Twirla contains Ethinyl Estradiol; Levonorgestrel.
Twirla has a total of 8 drug patents out of which 5 drug patents have expired.
Expired drug patents of Twirla are:
- US8883196
- US7045145
- US8221784
- US7384650
- US8221785
Twirla was authorised for market use on 14 February, 2020.
Twirla is available in system;transdermal dosage forms.
Twirla can be used as a transdermal method of contraception.
The generics of Twirla are possible to be released after 26 August, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 14, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 14 February, 2020
Treatment: A transdermal method of contraception
Dosage: SYSTEM;TRANSDERMAL
TWIRLA family patents
